Generic Name: risankizumab
Brand Name: TBC
Manufacturer: AbbVie Corporation
Indications: Psoriasis, moderate to severe plaque
Manufacturer Requested Reimbursement Criteria1:
That risankizumab be reimbursed for adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Submission Type: New
Project Status: Pending
Call For Patient Input: September 19, 2018
Patient Input Closed: November 8, 2018
Anticipated Date: October 18, 2018
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.